evipedia.aidev
← Back

Tribulus terrestris for Health & Longevity

Evidence Review created on 08/12/2026 using AI4L / Grok 4

Also known as: Puncture Vine, Goathead, Caltrop, Gokshura, Bai Ji Li, Gokhru

Motivation

Tribulus terrestris is a spiny annual herb long used in Ayurvedic and traditional Chinese medicine for vitality, urinary health, and sexual function. Today it is sold widely as a dietary supplement marketed for libido, erectile performance, athletic recovery, and sometimes as a “natural testosterone booster.” Its main active plant compounds are saponins (soap-like plant molecules), though product content varies substantially by plant part, geography, and extraction.

Interest among health- and longevity-oriented adults comes from a simple tension: traditional use and aggressive commercial claims sit next to mixed modern trial data. Some controlled studies report improved sexual function scores in men with mild-to-moderate erectile difficulties and in women with low desire, while systematic reviews find little robust evidence that Tribulus terrestris raises testosterone in adults with already-normal testosterone levels. Parallel work explores blood sugar and lipid effects in type 2 diabetes, with early human signals and limited sample sizes.

This review examines the clinical and mechanistic evidence for Tribulus terrestris as a health and longevity intervention—what benefits appear under controlled conditions, how strong that evidence is, what risks and interactions matter, and how practical protocols and monitoring are framed when people choose to use it.

Benefits - Risks - Protocol - Conclusion

High-level overviews and expert discussions that frame Tribulus terrestris in sexual health, safety, and plant-drug science.

No dedicated deep-dive articles on Tribulus terrestris were found from Peter Attia or Lifespan.io. Chris Kresser discusses Tribulus only briefly in an andropause (age-related male hormone decline) podcast covering LH (luteinizing hormone) and testosterone, not as a full evidence review. Life Extension content was limited to product pages rather than substantial evidence essays.

Grokipedia

  • Tribulus terrestris

    Broad botanical and use overview covering traditional medicine, saponins (including protodioscin), and the limited human evidence for testosterone elevation.

Examine

  • Tribulus terrestris

    Evidence-graded human outcomes for sexual function, hormones, performance, and metabolic markers, plus common dose ranges of 750–1,500 mg/day.

ConsumerLab

No dedicated ConsumerLab article for Tribulus terrestris was found as of 2026-08-12. Coverage appears only within broader multi-ingredient sexual-enhancer product reviews rather than a primary monographs page for the herb.

Systematic Reviews

Recent systematic reviews and meta-analyses assessing Tribulus terrestris for sexual function, hormones, fertility, and sport biomarkers (no human safety-focused systematic review was identified in PubMed as of this search).

Mechanism of Action

Tribulus terrestris preparations concentrate steroidal saponins (notably protodioscin and related furostanols), flavonoids, and alkaloids. In traditional marketing, saponins were said to raise luteinizing hormone and thereby testosterone. Human randomized trials and systematic reviews generally do not support a clinically meaningful testosterone rise in men with normal baseline androgens; any small increases reported in hypogonadal subgroups (men with low sex-hormone levels) have been modest (on the order of tens of ng/dL).

More plausible pathways for sexual-function effects include enhanced endothelial nitric oxide (NO) signaling via endothelial nitric oxide synthase (eNOS) → NO → cyclic guanosine monophosphate (cGMP, a second messenger that relaxes smooth muscle), improved penile smooth-muscle tone, and possible central or peripheral effects on desire that are not strictly androgen-dependent. Antioxidant and anti-inflammatory actions of saponins and flavonoids appear in preclinical models and may contribute to sperm-parameter or metabolic findings.

Metabolic hypotheses include improved insulin sensitivity and lipid handling in diabetic models; human data remain preliminary. Pharmacokinetics in humans are poorly characterized: half-life, bioavailability, and primary cytochrome P450 (CYP) metabolites of whole extracts are not standardized across products. In vitro work and case reports suggest moderate CYP3A4 (a major liver enzyme that metabolizes many drugs) inhibition potential, relevant to statin coadministration. Tissue distribution of individual saponins is largely described in animals, not multi-compartment human studies. Extract composition (plant part, geography, saponin percent) drives most pharmacologic variability.

Historical Context & Evolution

Tribulus terrestris (Zygophyllaceae) is native to Mediterranean, African, and Asian dry regions and is known as puncture vine, goathead, or caltrop for its sharp burs. Ayurvedic texts (as gokshura) and traditional Chinese medicine (as bai ji li) used fruit, leaf, and root as diuretics, tonics, and remedies for urinary complaints, kidney stones, and vitality. Aphrodisiac and fertility uses predate modern sports nutrition by centuries.

Western commercial interest accelerated in the late twentieth century when Eastern European athletic and bodybuilding markets promoted saponin-rich extracts as non-hormonal performance aids. Claims shifted toward testosterone, libido, and muscle support. Early animal work sometimes showed androgenic signals; human trials from the 2000s–2010s were smaller, heterogeneous in dose and extract standardization, and often industry-linked.

Subsequent placebo-controlled trials (e.g., Santos et al. 2014 null for erectile dysfunction and testosterone at 800 mg/day for 30 days; Kamenov et al. 2017 positive IIEF signal with a standardized Bulgarian extract over 12 weeks) produced divergent results. Systematic reviews through 2014–2025 tempered the testosterone claim while leaving room for modest sexual-function benefits independent of androgen change. Toxicity awareness also evolved: livestock photosensitization (light-triggered skin damage after plant ingestion, “geeldikkop”) was long known, and rare human case reports of kidney, liver, and muscle injury entered the literature in the 2010s–2020s. The modern picture is traditional prestige, commercial overclaim, and an evidence base still limited by product heterogeneity.

Expected Benefits

Medium 🟩 🟩

Improved erectile function scores in men with mild-to-moderate erectile dysfunction ⚠️ Conflicted

Randomized trials and recent systematic reviews report IIEF/IIEF-5 (abridged IIEF) gains versus placebo in men with mild-to-moderate erectile dysfunction (ED, difficulty achieving or maintaining erection), often at 400–1,500 mg/day for 4–12 weeks. Results conflict: null trials exist (e.g., 800 mg/day for 30 days). Extract quality and baseline severity likely matter. Benefits appear largely independent of large testosterone changes.

Magnitude: Meta-analyzed mean difference roughly +3 IIEF-5 points versus placebo in positive analyses (e.g., Suharyani et al. 2025); individual trials range from null to clinically noticeable.

Improved female sexual function scores (desire/arousal domains)

Placebo-controlled trials in pre- and postmenopausal women with low desire or broader female sexual dysfunction report Female Sexual Function Index (FSFI) improvements over weeks to months. A systematic review of five randomized controlled trials (RCTs; n=279) found consistent directional gains despite heterogeneity. Short-trial adverse events resembled placebo.

Magnitude: FSFI scores improve over 4–12 weeks in several RCTs of women with low desire or female sexual dysfunction; the literature reports no single pooled outcome figure.

Low 🟩

Support for sperm parameters in idiopathic (unexplained-cause) male infertility

A systematic review of seven studies found improved sperm count, motility, and/or morphology in most reports, though designs and bias risk varied. Mechanisms may be antioxidant rather than systemic testosterone elevation. Larger standardized RCTs remain limited.

Magnitude: Semen parameters improve directionally in 6 of 7 reviewed studies; the literature reports no uniform absolute outcome figure.

Favorable shifts in blood glucose and some lipids in type 2 diabetes

One double-blind RCT in women with type 2 diabetes (1,000 mg/day for 3 months) lowered fasting/postprandial glucose and total cholesterol/low-density lipoprotein (LDL) versus placebo, without clear triglyceride or high-density lipoprotein (HDL) benefit. Human replication is sparse.

Magnitude: Fasting and postprandial glucose and LDL/total cholesterol fell versus placebo in one 3-month RCT (n=98); the literature reports no multi-trial pooled outcome figure.

Possible lipid-profile improvements in physically active men

A systematic review of sport/health biomarker trials noted lipid improvements in some active men on Tribulus, with weaker effects on muscle-damage and hormonal markers. Results are inconsistent across small studies.

Magnitude: Lipid profiles improve in a subset of small athletic trials; the literature reports no consistent outcome figure.

Speculative 🟨

Athletic performance, body composition, or recovery via testosterone

Claims of muscle, strength, or recovery via testosterone lack robust human support. Reviews find no reliable testosterone rise from Tribulus alone in healthy men; performance RCTs are mixed to null.

Benefit-Modifying Factors

  • Baseline androgen status: Small testosterone rises, when reported, cluster in hypogonadal rather than eugonadal men (those with already-normal sex-hormone levels); sexual-function benefits can still appear without large hormone changes.

  • Erectile dysfunction severity: Positive trials mainly enroll mild-to-moderate ED; severe organic ED (vascular, neurologic) is less likely to respond to a mild botanical alone.

  • Sex and life stage: Female sexual-function RCTs include pre- and postmenopausal cohorts; desire-domain responses may differ by menopausal status and concurrent hormone therapy.

  • Extract standardization: Protodioscin/furostanol content and plant part (fruit vs aerial) vary widely; standardized European extracts used in positive ED trials may not match generic powders.

  • Metabolic disease: Glucose and lipid signals are reported mainly in type 2 diabetes; euglycemic adults (those with normal blood sugar) have little evidence for metabolic benefit.

  • Age: Older adults in ED trials can show IIEF gains, but polypharmacy (use of multiple medications at once) and organ-function declines raise interaction and safety stakes.

Potential Risks & Side Effects

Medium 🟥 🟥

Gastrointestinal upset

Nausea, stomach pain, gastric irritation, and reflux are the leading adverse effects in trials and monographs. They are usually mild and reverse with dose reduction or stopping. Short trials (up to about 3 months) often show overall adverse-event rates similar to placebo.

Magnitude: Mild gastrointestinal complaints are the most common trial and consumer adverse effects; the literature reports no consistent incidence figure across products and doses.

Low 🟥

Blood-pressure or blood-sugar lowering (additive with drugs)

Vasodilatory and hypoglycemic signals support additive hypotension (low blood pressure) or hypoglycemia (low blood sugar) with antihypertensives or diabetes drugs. Clinical event rates are incompletely quantified but are standard monograph cautions.

Magnitude: Directionally additive blood-pressure or glucose lowering in users on antihypertensives or diabetes drugs; the literature reports no outcome figure.

In vitro data suggest moderate CYP3A4 inhibition by Tribulus extracts. A published rhabdomyolysis case (severe muscle breakdown) involved a long-term atorvastatin user who started Tribulus, consistent with raised statin exposure. Controlled interaction trials in humans remain sparse.

Magnitude: Interaction risk is directionally higher with CYP3A4-metabolized statins; the literature reports no incidence figure from large safety series.

Speculative 🟨

Hepatotoxicity or nephrotoxicity (liver or kidney injury)

Isolated cases report liver injury or kidney tubule damage after high-dose or multi-ingredient products. Livestock organ toxicity is known at high intakes. Basis is cases and animal data, not controlled trials.

Priapism (prolonged erection) and hormonal theoretical risks

Rare priapism appears in monographs. Hormone-sensitive prostate concerns are theoretical given weak human testosterone effects.

Neurological case reports

Isolated case reports and monographs note rare neurological toxicities with Tribulus-containing products. Basis is case-level and multi-ingredient exposures, not controlled trials.

High-dose sleep disturbance or elevated heart rate

Consumer and military-safety briefings note sleep disturbance, fatigue, or elevated heart rate at intakes above about 1,000 mg/day in some reports. Evidence is uncontrolled and dose–response is poorly mapped.

Risk-Modifying Factors

  • Concomitant CYP3A4-substrate drugs: Statins (atorvastatin, simvastatin), some calcium-channel blockers, and other CYP3A4 substrates increase interaction risk if Tribulus inhibits the enzyme.

  • Baseline renal or hepatic impairment: Case reports of organ injury make reduced reserve a risk amplifier; avoid or use only with specialist oversight.

  • Diabetes or antihypertensive therapy: Additive glucose or blood-pressure lowering may unmask hypoglycemia or orthostatic symptoms (dizziness on standing).

  • Sex and pregnancy status: Pregnancy use is considered possibly unsafe in major monographs; avoid in pregnancy and lactation due to insufficient safety data and traditional uterine activity claims.

  • Age and polypharmacy: Older adults face higher drug–herb interaction density and lower organ reserve.

  • Product quality / multi-ingredient testosterone-support formulas: Adulteration with undeclared phosphodiesterase-5 (PDE5) inhibitors or other drugs is documented in sexual-enhancement products and multiplies risk.

Key Interactions & Contraindications

  • Statins via CYP3A4 (atorvastatin, simvastatin, lovastatin): Caution — possible increased statin exposure and myopathy (muscle disease) or rhabdomyolysis risk; avoid combination or use only with clinical monitoring and CK (creatine kinase, a muscle-injury enzyme) awareness.

  • Antihypertensives (ACE inhibitors (angiotensin-converting enzyme blockers), ARBs (angiotensin receptor blockers), calcium-channel blockers, diuretics): Caution — additive blood-pressure lowering; monitor for dizziness or hypotension.

  • Antidiabetic agents (metformin, sulfonylureas, insulin, SGLT2 inhibitors (sodium-glucose cotransporter-2 drugs)): Caution — additive glucose lowering; monitor capillary glucose when starting or stopping.

  • Diuretics (furosemide, hydrochlorothiazide): Caution — traditional diuretic activity may amplify fluid/electrolyte shifts.

  • Antiplatelet/anticoagulant context (clopidogrel noted in herbal-formula case context): Caution — monograph-level concern for altered clotting risk with multi-herb products containing tribulus; evidence for isolated Tribulus is limited.

  • Other libido / PDE5-pathway agents (sildenafil, tadalafil, yohimbine): Monitor — theoretical additive vascular or prolonged-erection risk; start conservatively if combined.

  • Supplements with additive metabolic effects (berberine, high-dose cinnamon, other hypoglycemics): Monitor — combined glucose lowering.

  • Over-the-counter (OTC) blood-pressure or glucose-active agents (decongestants, NSAIDs (nonsteroidal anti-inflammatory drugs), diuretic teas): Caution — additive pressure or metabolic shifts possible; isolated-Tribulus evidence is limited, but monographs extend cautions to self-selected OTC use.

Populations who should avoid Tribulus terrestris:

  • Pregnancy and breastfeeding
  • Known significant hepatic or renal disease
  • Planned major surgery (stop in advance per clinician guidance due to blood-pressure/glucose and interaction unknowns)
  • Hormone-sensitive prostate cancer unless cleared by the treating oncologist
  • Children and adolescents (insufficient safety data)

Risk Mitigation Strategies

  • Start low, reassess: Protocols often begin near 250–500 mg/day of a characterized extract for several days before escalating toward 750–1,500 mg/day to limit gastrointestinal (GI) intolerance.

  • High-risk drug pairs: Combination with CYP3A4-metabolized statins is generally reserved for clinician-reviewed settings to reduce myopathy and rhabdomyolysis risk; non-interacting lipid strategies are used when both goals matter.

  • Metabolic co-monitoring: With antihypertensives or diabetes drugs, home blood pressure and glucose are commonly tracked during the first 1–2 weeks to detect additive hypotension or hypoglycemia.

  • Organ-function baseline: Baseline CMP (comprehensive metabolic panel: liver enzymes, creatinine/eGFR (estimated glomerular filtration rate)) is typically obtained before sustained use to screen for liver or kidney injury risk.

  • Single-ingredient, tested products: Third-party–tested single-herb capsules are favored over proprietary “male enhancement” blends to reduce adulteration risk.

  • Time-limited trials: Unsupervised continuous use is commonly limited to 8–12 weeks pending labs and symptom review, mitigating unknown long-term organ and interaction risks given sparse chronic-safety data.

  • Stop rules: Jaundice (yellowing of skin or eyes), dark urine, severe muscle pain, marked edema (swelling), or unexplained fatigue are stop signals for discontinuation and urgent clinical evaluation.

Therapeutic Protocol

  • Common studied range: 750–1,500 mg/day of Tribulus terrestris extract is the most cited clinical range; 750 mg/day is frequently used.

  • Standardized extract example: Trials of Bulgarian fruit extract used ~1,500 mg/day (e.g., 250 mg tablets, 2 tablets three times daily) standardized to furostanol saponins.

  • Timing: Often split with meals (2–3 doses/day) to reduce GI upset; no established circadian optimum.

  • Half-life / kinetics: Human half-life of whole-extract saponins is not well defined; split dosing is empirical rather than pharmacokinetics-driven.

  • Single vs split dose: Split dosing preferred for gastrointestinal tolerance and to approximate multi-dose trial regimens.

  • Sex differences: Female sexual-function protocols in RCTs used varied (sometimes lower) extract amounts; male ED trials more often used 750–1,500 mg/day.

  • Age: Older adults may use the same milligram range but require stricter interaction screening and lab baselines.

  • Baseline labs as protocol gates: Reasonable liver/kidney function is typically confirmed first; when sexual-function goals dominate, optional morning total/free testosterone and sex hormone-binding globulin (SHBG) help avoid attributing unrelated hormone changes to the herb.

  • Health conditions: In diabetes, glucose-lowering regimens are coordinated when Tribulus is added; in ED with cardiovascular disease, Tribulus is not a substitute for guideline ED evaluation.

  • Competing approaches: Some integrative clinicians pair lifestyle/sleep/resistance training first and treat Tribulus as a time-limited add-on; conventional ED care prioritizes PDE5 inhibitors, which have far stronger efficacy data.

  • Genetics: No established genetic variants that change drug metabolism guide Tribulus dose; protocol choice is empirical rather than genotype-based.

Discontinuation & Cycling

  • Duration intent: Typically short- to medium-term (weeks to a few months) for sexual-function trials, not an established lifelong longevity drug.

  • Withdrawal: No classic withdrawal syndrome is described; effects are expected to wane after clearance of saponins and related actives.

  • Tapering: Abrupt stop is usually acceptable; a short taper is sometimes used after high doses if gastrointestinal symptoms flare or if the user prefers a gradual stop.

  • Cycling: Some sports-nutrition practices cycle 4–8 weeks on / 2–4 weeks off; evidence that cycling preserves efficacy is anecdotal.

  • Rechallenge: After labs or drug changes, restart protocols typically re-titrate from a lower dose and reassess interactions.

Sourcing and Quality

  • Plant part and extract ratio: Products that state fruit or aerial-part extract ratio and percent steroidal saponins/protodioscin are commonly selected over unlabeled powder.

  • Third-party testing: USP, NSF, Informed-Sport, or equivalent identity/purity testing is a common quality marker; sexual-enhancement products have a documented history of adulteration.

  • Undeclared drug blends: Proprietary “male enhancement” formulas without full quantitative labeling are commonly avoided because adulteration risk is documented in that product class.

  • Geographic chemical profile: Saponin profiles differ by growing region; clinical positive ED data often used specific Eastern European standardized extracts—generic equivalence is not guaranteed.

  • Storage: Dry, cool storage protects plant extracts from moisture degradation.

  • Reputable channels: Established supplement brands with batch COAs (certificates of analysis) are preferable to anonymous marketplace powders.

Practical Considerations

  • Time to effect: Sexual-function trials often reassess at 4–12 weeks; benefits before 2 weeks are uncommon in controlled data.

  • Common pitfalls: Expecting large testosterone or hypertrophy (muscle-size growth) gains; using adulterated multi-ingredient products; ignoring statin interactions; comparing dissimilar extract strengths.

  • Regulatory status: Sold as a dietary supplement in the US (not FDA-approved to treat ED or hypogonadism (low sex-hormone production)); structure/function claims are lightly regulated relative to drugs.

  • Cost and access: Generally inexpensive (often well under the cost of branded PDE5 therapy); quality-tested products cost more than bulk powder.

  • Expectation setting: Effect sizes, when present, are modest next to prescription ED therapies; null personal trials are common.

Interaction with Foundational Habits

  • Sleep: No direct sleep-architecture effect established; improved sexual satisfaction could indirectly affect relationship stress and sleep quality for some couples (indirect, modest).

  • Nutrition: Take with food if GI-sensitive; in diabetes contexts, pair with carbohydrate-aware eating because of possible glucose-lowering synergy (potentiating metabolic control, monitor hypoglycemia risk).

  • Exercise: Does not reliably enhance strength or hypertrophy in RCTs; resistance training and energy balance remain primary for body composition (none to blunting of performance claims).

  • Stress management: Libido is highly stress-sensitive; addressing sleep debt, alcohol, and psychological stress often dominates botanical effects (indirect, complementary).

Monitoring Protocol & Defining Success

Before a multi-week course, establish baseline organ function and, when sexual or hormonal goals dominate, a morning hormone panel. Repeat safety labs after the first month of continuous use, then as clinically indicated if use continues. Home metrics (validated sexual-function questionnaires, blood pressure, glucose if diabetic) provide earlier feedback than annual labs alone.

Ongoing monitoring at about 4 weeks, again near 8–12 weeks if continuing, then every 3–6 months only if long-term use is elected despite limited chronic-safety data. Success is defined against the individual’s baseline: meaningful IIEF or FSFI domain change, stable or improved metabolic markers when relevant, and absence of liver, kidney, or muscle adverse signals—not a target testosterone number, which Tribulus rarely moves in eugonadal adults.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT / AST (liver enzymes) Often targeted near lower half of lab range (e.g., ALT ≲30 U/L men, ≲25 U/L women in functional practice) Detect hepatotoxicity early Alanine/aspartate aminotransferase; conventional lab upper limits are often ~40–50 U/L (higher than functional targets); repeat if symptoms or multi-herb use
Creatinine / eGFR eGFR ≥90 mL/min/1.73 m² ideal; track personal baseline if 60–89 Case reports of tubular injury Estimated glomerular filtration rate; fasting not required; avoid intense exercise 24 h before if CK also drawn
Fasting glucose / HbA1c Fasting glucose ~70–90 mg/dL functional aim; HbA1c individualized Additive glycemic effects Glycated hemoglobin (longer-term glucose average); essential if on antidiabetic drugs; continuous glucose monitor optional
Blood pressure ~110–120 / 70–80 mmHg typical longevity-oriented office aim Additive hypotensive potential Home AM/PM series better than single clinic reading
CK (if on statin or muscle symptoms) Within lab reference; investigate upward trends Rhabdomyolysis interaction risk Draw if myalgias (muscle aches); compare to personal baseline
Total / free testosterone + SHBG (optional) Age- and lab-specific; free T often more informative Document that benefits ≠ large T rise Morning draw; not required for every user

Qualitative markers:

  • Sexual desire, erectile rigidity, and satisfaction (IIEF-5 or FSFI short forms)
  • Gastrointestinal tolerance (nausea, reflux)
  • Energy and training recovery (without expecting ergogenic—performance-enhancing—effects)
  • Muscle pain or dark urine (stop immediately if present)

Emerging Research

  • Oligospermia (low sperm count) Phase 4 program: NCT06260007 is recruiting (~204 men) to test Tribulus terrestris–based products for oligospermia efficacy and safety—could strengthen or weaken fertility claims.

  • Acute sport performance: NCT07164547 completed acute anaerobic/sprint testing in combat athletes; results may clarify short-term performance effects beyond hormone marketing.

  • Female sexual desire formulations: Prior completed trials (e.g., NCT01971099, NCT01407445) inform menopausal and low-desire use; larger multi-center replications are still needed.

  • Safety pharmacology: Case-driven research on CYP3A4 inhibition and organ toxicity (e.g., Huff et al. 2024 atorvastatin–Tribulus rhabdomyolysis) may redefine co-medication rules more than efficacy trials alone.

  • Extract standardization: Comparative work on protodioscin content versus clinical response could explain historical trial conflicts and either rehabilitate or further limit generic products.

Conclusion

Tribulus terrestris is a traditional vitality herb now sold mainly for sexual function and, less credibly, for testosterone and athletic enhancement. Controlled human evidence supports a possible benefit on erectile function scores in men with mild-to-moderate erectile difficulties and on female sexual function scores in several small trials—effects that appear largely independent of large testosterone changes. Systematic reviews through 2025 still find no robust testosterone-raising effect in men with normal baseline testosterone, and sport-performance or body-composition benefits remain unconvincing.

Metabolic signals (glucose and some lipids in type 2 diabetes) are intriguing but rest on limited trials. Safety in short studies is generally acceptable, with gastrointestinal upset the main complaint, yet rare case reports of liver, kidney, and muscle injury—and a plausible interaction with some cholesterol drugs that share the same liver-metabolizing pathway—keep risk non-zero, especially when several medications are taken together or when products are poorly made multi-ingredient blends. Product heterogeneity (plant part, saponin content, adulteration in the sexual-enhancement aisle) remains a central barrier to firm conclusions.

For health- and longevity-oriented adults, the evidence portrays Tribulus terrestris as a time-limited, modest sexual-function add-on candidate rather than a foundational longevity molecule or a reliable way to raise testosterone. Quality of extract, interaction screening, and objective monitoring determine whether any individual signal is real or noise.

Top - Benefits - Risks - Protocol